Plus Sale Purchase Of Stock from 2010 to 2025

PSTV Stock  USD 1.26  0.03  2.44%   
Plus Therapeutics Sale Purchase Of Stock yearly trend continues to be fairly stable with very little volatility. Sale Purchase Of Stock will likely drop to about -152.1 K in 2025. During the period from 2010 to 2025, Plus Therapeutics Sale Purchase Of Stock regression line of quarterly data had mean square error of 19.9 T and geometric mean of 0.00. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
2001-03-31
Previous Quarter
0.0
Current Value
374 K
Quarterly Volatility
13.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Latest Plus Therapeutics' Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Plus Therapeutics over the last few years. It is Plus Therapeutics' Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Pretty Stable
   Sale Purchase Of Stock   
       Timeline  

Plus Sale Purchase Of Stock Regression Statistics

Arithmetic Mean437,060
Geometric Mean0.00
Coefficient Of Variation1,007
Mean Deviation2,387,110
Median(184,000)
Standard Deviation4,399,824
Sample Variance19.4T
Range18.3M
R-Value0.20
Mean Square Error19.9T
R-Squared0.04
Significance0.45
Slope189,024
Total Sum of Squares290.4T

Plus Sale Purchase Of Stock History

2025-152.1 K
2024-144.9 K
2023-126 K
2021null
2020M
201916 M
2018-1.5 M

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Sale Purchase Of Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Sale Purchase Of Stock-144.9 K-152.1 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.